TET Systems has built a network of authorized suppliers providing research tools and services to facilitate your R&D projects. Licensees have access to a broad range of reagents, services or animals comprising the Tet Technology.
Biospecimen Laboratories Co. Ltd. and TET Systems GmbH & Co. KG sign Marketing Agreement for the Tet Technology in Japan
Biospecimen Laboratories Co. Ltd., a privately-held, Japan-based trading and consulting company, and TET Systems GmbH & Co. KG, a privately-held, German-based biotech company, announced today that they have entered into a marketing agreement, effective July 1, 2024. This agreement will replace the previous marketing alliance between BizCom Japan, Inc. and TET Systems.
Biospecimen Laboratories Co. Ltd. (BSL), was founded by Dr. Hiroyasu Nakatani. During his time at BizCom Japan, Inc. Dr. Nakatani was the main representative for TET Systems (TET). He was instrumental in introducing the TET technology to the life science market in Japan and in establishing alliances with Japanese companies and public institutions. BSL will use his experience to exclusively market the Tet Technology for TET Systems GmbH & Co. KG in Japan.
TET would like to thank BizCom Japan, Inc. for its outstanding support both of Dr. Nakatani and TET Systems over the past years. All parties involved are convinced that Dr. Nakatani is the perfect solution to manage TET Systems` existing business and to form new relationships with Japanese customers.
NOTE TO JAPANESE CUSTOMERS:
From July 1, 2024, please contact:
Biospecimen Laboratories, Inc.
1-5-10-105, Nakamagome, Ota-ku Tokyo 143-0027
TEL: 03-3775-5155
Mail: license@biospecimen.co.jp
About Biospecimen Laboratories, Co. Ltd.
Biospecimen Laboratories Co. Ltd. is a trading and consulting company based in Tokyo, Japan.
About TET Systems GmbH & Co. KG
TET Systems GmbH & Co. KG is a privately held company located in Heidelberg, Germany. TET Systems GmbH & Co. KG was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the TET Technology, the most widely used method to control gene expression in higher organisms. TET Systems GmbH & Co. KG owns a broad patent portfolio. To date, more than 500 organizations have licensed the TET Technology including large pharmaceutical companies, academic institutions or research foundations and are long-standing partners.